Once again, Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) are running into roadblocks trying to win over payers with their new drug for severe eczema. The latest frustration is occurring in the U.K., where a government watchdog decided the drug would not be cost effective.

The cost estimates for the drug, which is known as Dupixent, were considered “too high” to be a “good use of National Health Services resources,” according to a draft guidelines that were released on Tuesday by the National Institute for Health and Care Excellence. The annual cost, based on list price, would be about $23,000 per year for 26 injections, according to a briefing report.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy